During the past decade, Vancouver Stroke Program conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vancouver Stroke Program" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Vancouver Stroke Program" are "Embolic Stroke of Undetermined Source" (1 trials), "Minor Ischemic Stroke" (1 trials) and "Transient Ischemic Attack" (1 trials). Many other conditions were trialed in "Vancouver Stroke Program" in a lesser frequency.

Most popular intervention types in "Vancouver Stroke Program" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Acetylsalicylic acid" (1 trials) and "Dabigatran" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vancouver Stroke Program" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Vancouver Stroke Program". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Vancouver Stroke Program, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Vancouver Stroke Program, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".